Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
- Conditions
- Platinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)
- Registration Number
- EUCTR2007-003089-16-DE
- Lead Sponsor
- AGO Research GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- 72
Women, 18 years and older, written (signed and dated) informed consent
Histological confirmed epithelial ovarian cancer, primary cancer of the peritoneum or fallopian tube
Up to three prior chemotherapies, at least one platinum based chemotherapy
Platinum refractory or resistant ovarian cancer (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)
Measurable or non-measurable disease
Elevated CA°125 level (> 2 x ULN in case of normal CA°125 after prior chemotherapy; or = 2 x nadir CA°125 value after prior chemotherapy, when CA°125 levels remained elevated above normal) in case of non-measurable disease
ECOG performance status 0-2
Negative pregnancy test within 5 days before randomization and adequate contraception in women with childbearing potential
Adequate organ function as defined by the following criteria:
•Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase [SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) ?2.5 x upper limit of normal (ULN). If liver function abnormalities are due to underlying malignancy, then AST and ALT may be ?5 x ULN
•Total serum bilirubin ?1.5 x ULN
•Prothrombin time (PT) and partial thromboplastin time (PTT) ?1.5 x ULN
•Serum albumin ?3.0 g/dL
•Absolute neutrophil count (ANC) ?1500/?L
•Platelets ?100,000/?L
•Hemoglobin ?9.0 g/dL
•Serum creatinine ?1.5 x ULN
•TSH within normal range
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
Resolution of all toxic effects of any prior chemotherapy, surgical procedures, radiotherapy, or other cancer related therapies to NCI CTCAE (Version 3.0) grade ?1 and to the baseline laboratory values as defined in inclusion criterion (see before)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Borderline tumor of the ovaries
Acute or chronic infection
Any required concurrent cancer chemotherapy or antineoplastic endocrine therapy or radiotherapy
Exposure to investigational trial medication, cancer chemo- or radiotherapy within the last 28 days prior to start of study treatment
Known or suspected hypersensitivity to investigational compound
Second malignancy interfering with prognosis of the patient
Inadequate renal function (Creatinine >1.5 x ULN)
Inadequate hepatic function (ASAT, ALAT, GGT >2.5 x ULN, in case of liver metastases >5.0 x ULN; Bilirubine >1.5 x ULN)
Platelets < 100.000 /µl; ANC < 1.500 /µl
Cachectic patients with a body weight <45 kg
Patients requiring parenteral nutrition
Patients with ileus within the last 28 days
Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event
Current treatment with therapeutic doses of anticoagulant (low dose Cumarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed)
Current treatment with CYP3A4 inhibitors or –inducers
Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
Ongoing cardiac dysrhythmias of NCI CTCAE grade ?2, atrial fibrillation of any grade, or prolongation of the QTc interval to >470 msec for females
•Left ventricular ejection fraction (LVEF) ?50% as measured by echocardiogram (ECHO)
•NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment
Evidence of neurological signs/symptoms suggestive of brain metastases, spinal cord compression, or new evidence of brain or leptomeningeal disease
Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness
Patients with any other severe concurrent disease, which is an undue risk for the patient by participating in the present study
Any further condition which according to the investigator results in an undue risk of the patient by participating in the present study
Major surgery, radiation therapy, or systemic therapy within 3 weeks of first study treatment. At least 7 days should elapse from the time of minor surgical procedure including placement of an access device or fine needle aspiration before randomization into this study can occur.
Wounds that have not completely healed, active ulcer(s), or bone fracture(s).
Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
Prior radiation therapy to >25% of the bone marrow.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Objective response (CR, PR) evaluated by RECIST criteria in case of measurable disease, and by tumor marker (CA°125) in case of non-measurable disease.;Secondary Objective: Tolerability, Toxicity, Time to progression, Overall survival, Duration of tumor response, Stable disease<br><br>Additional objectives:<br>Translational research (target expression in tumor tissues if available; IHC for VEGFR, PDGFR and c-kit),<br>Cytokine profile in serum before and during therapy and proteomic analysis, if samples are available,<br>Circulating endothelial progenitor cells,<br>Proteomic analysis of serum samples,<br>Wound healing assay;Primary end point(s): The primary endpoint is the confirmed tumor response. Responders are patients with an overall response (complete response [CR] and partial response [PR]) according to Response Evaluation Criteria in Solid Tumors” [RECIST] in case of measurable disease, and according to CA°125 criteria as recommended by the GCIG in case of non-measurable disease
- Secondary Outcome Measures
Name Time Method